Constipation Treatment Market Size 202 Incredible Possibilities of Growth and Opportunities Outcomes Analysis and Forecast to 2027

Being an idiopathic condition, there is uncertainty regarding the causes of this disease. However, the two disorders that cause constipation are pelvic floor dysfunction, and colonic inertia.

Constipation is a chronic disorder which causes abnormal bowel movements and results in hardened feces which persists for several weeks or even longer. It is defined medically as fewer than three stools per week and severe constipation as less than one stool per week. It causes infrequent stools, difficult stool passage with pain and stiffness. Acute constipation may cause blocking of the intestine, which may even require surgical intervention. The symptoms of constipation include bloating, lower abdominal discomfort, rectal bleeding, anal fissures caused by hard stools, incomplete evacuation, gastric pain, and strain during the bowel movement.

Chronic idiopathic constipation (CIC) is a severe form of constipation and it is a gastrointestinal disorder which leads to discomfort while defecating. It is often seen in geriatric populations especially adults. Diagnosis of chronic idiopathic constipation is tedious due to the dearth of physiological evidences and physicians try to diagnose the condition by evaluating parameters like weight, blood in stool, and low blood count.

Download Sample PDF Of Report@

Constipation Treatment Competitive Analysis:-

AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International Inc., Bayer AG, Pfizer Inc., Sanofi, Synergy Pharmaceuticals, Inc., Janssen Pharmaceutical Company, Boehringer Ingelheim GmbH, and Ironwood Pharmaceuticals, Provided in this report. These players have adopted various strategies including expansions, mergers & acquisitions, joint ventures, new product launches, and collaborations to gain a strong position in the industry.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis :-

The factors such as rising expenditure in R&D activities for the developments of innovative drugs, developments in healthcare infrastructure, rise in the aged and geriatric population, sedentary lifestyle, changing dietary habits, and inadequate consumption of fast food in high quantity, frequently are leading to rise in demand for constipation treatment market growth in coming years.

Along with the growing complexity in the healthcare domain there is need to provide better treatment and solutions to the upcoming challenges. Presence of healthcare professionals with optimum knowledge and expertise, high prevalence IBS, chronic constipation and the development of latest drugs and treatment procedures and advancements associated with gastrological mechanisms have revolutionized the growth of constipation treatment market. The irritable bowel syndrome (IBS) is a chronic, recurring gastrointestinal tract disorder that is found affecting between 7%–18% of the population worldwide. Treatment of IBS currently is a multifaceted approach, as a direct single approach therapy hasn’t been effective so far. Hence, the multi approach therapy is a combination therapy consisting of changes in diet, exercise, stress management, and medication. Efforts are being made and various key players are engaged in R&D activities associated with getting a direct breakthrough treatment for IBS and chronic constipation which creates lucrative opportunities in the market.

Recent developments and innovations to boost the growth rate:-

The prime objective of constipation treatment is to normalize the frequency and quantity of stool in order to promote normal defecation. Heavy investments in R&D and numerous studies on pharmacologic and non-pharmacologic treatments for constipation proven successful in terms of overcoming some of the challenges like temporary status and efficacy and comparatively are better than their predecessors who have shown mediocre performance and lack of efficacy. However, the latest innovations such as enterokinetic agents and intestinal secretagogues have shown positive outcomes being capable in delivering high efficacies and low incidences of adverse events. Research on biofeedback and surgical treatment have proved efficient as well as better quality of life for patients with refractory constipation. These factors would boost the market for constipation treatment.

For instance, Astellas Pharma, Inc. in working on a novel drug and submitted new drug application for Linaclotide for patients with chronic constipation in Japan. Similarly in January 2017, FDA announced approval for the Linzess manufactured by Allergan Plc. and Ironwood Pharmaceuticals and Tulane manufactured by Synergy Pharmaceuticals for the treatment of chronic idiopathic constipation

Inquiry for Buying@

Contact Info:
Name: David Correa
Email: Send Email
Organization: Allied Market Research
Address: 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States
Phone: 18007925285

Release ID: 89035274